tradingkey.logo
搜尋

Pacific Biosciences of California Inc

PACB
添加自選
1.395USD
+0.015+1.09%
收盤 07-23 16:00美東報價延遲15分鐘
433.13M總市值
虧損本益比TTM

Pacific Biosciences of California Inc

1.395
+0.015+1.09%
查看詳細走勢圖
TradingKey 圖表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.09%

5天

-6.38%

1月

+6.49%

6月

-45.93%

今年開始到現在

-25.40%

1年

-17.46%

關鍵數據
1.360今開
1.430最高
6.86M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
2.21%換手率
1.380昨收
1.360最低
7.58M成交額
虧損本益比靜
183.06市淨率
0.00%股息率 TTM
-15.65%ROA
2.73052週最高
0.92量比
-309.85M淨利潤
310.49M總股本
-0.4133每股盈餘TTM
2.36Beta
-273.55%ROE
0.96052週最低
5.07%振幅
32.30%毛利率
433.13M總市值
-0.82回報/風險
5.08%風險率

操作建議

Pacific Biosciences of California Inc當前公司基本面數據相對謹慎,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名108/200位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為2.46。中期看,股價處於下降通道。近一個月,市場表現較差,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Pacific Biosciences of California Inc評分

相關信息

行業排名
108 / 200
全市場排名
211 / 4547
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Pacific Biosciences of California Inc亮點

亮點風險
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入160.00M美元
估值低估
公司最新PE估值-3.39,處於3年歷史低位
機構減倉
最新機構持股192.85M股,環比減少9.18%
凱西‧伍德(木頭姊姊)持倉
明星投資者凱西‧伍德(木頭姊姊)持倉,最新持倉37.12M股

分析師目標

基於 8 分析師
買入
評級
2.458
目標均價
+75.59%
漲幅空間

Pacific Biosciences of California Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

收益預測

分析師評級

基於 8 分析師
買入
評級
2.458
目標均價
+75.59%
漲幅空間
強力買入
買入
持有
賣出
強力賣出

同行比較

88
總數
4
中位數
7
平均值
公司名稱
評級分佈
分析師數
Pacific Biosciences of California Inc
PACB
8
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
33
Thermo Fisher Scientific Inc
TMO
30
Veeva Systems Inc
VEEV
30
1
2
3
...
18

技術指標

技術指標
賣出(1)
中性(4)
買入(1)
指標
數值
方向
MACD(12,26,9)
-0.053
中性
RSI(14)
44.107
中性
STOCH(KDJ)(9,3,3)
21.469
中性
ATR(14)
0.094
低波動
CCI(14)
-95.582
中性
Williams %R
83.117
超賣
TRIX(12,20)
-0.079
賣出
StochRSI(14)
76.997
買入
移動平均線
賣出(6)
中性(0)
買入(0)
指標
數值
方向
MA5
1.396
賣出
MA10
1.455
賣出
MA20
1.548
賣出
MA50
1.428
賣出
MA100
1.449
賣出
MA200
1.711
賣出

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Pacific Biosciences of California Inc簡介

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
公司代碼PACB
公司Pacific Biosciences of California Inc
CEOHenry (Christian O)
網址https://www.pacb.com/

公司股東

持股股東
持股股東
佔比
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
其他
68.81%

常見問題

Pacific Biosciences of California Inc(PACB)的當前股價是多少?

Pacific Biosciences of California Inc(PACB)的當前股價是 1.40。

Pacific Biosciences of California Inc 的股票代碼是什麼?

Pacific Biosciences of California Inc的股票代碼是PACB。

Pacific Biosciences of California Inc股票的52週最高點是多少?

Pacific Biosciences of California Inc股票的52週最高點是2.73。

Pacific Biosciences of California Inc股票的52週最低點是多少?

Pacific Biosciences of California Inc股票的52週最低點是0.96。

Pacific Biosciences of California Inc的市值是多少?

Pacific Biosciences of California Inc的市值是433.13M。

現在Pacific Biosciences of California Inc(PACB)的股票是買入、持有還是賣出?

根據分析師評級,Pacific Biosciences of California Inc(PACB)的總體評級為買入,目標價格為2.46。

Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是多少

Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是-1.82。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有